Lactate Enzyme Overexpression Enhances Remyelination in Animal Models

The Metabolic Bottleneck in Myelin Repair

Demyelinating diseases such as multiple sclerosis represent a leading cause of non-traumatic neurological disability in young adults [1]. While current disease-modifying therapies effectively suppress acute neuroinflammation, they do not repair the existing plaques where mature oligodendrocytes have been destroyed [2, 3]. Without intact myelin, exposed axons lose vital metabolic support and eventually undergo irreversible transection, driving progressive clinical decline [2, 4]. Recent investigations suggest that the failure of oligodendrocyte precursor cells to mature and remyelinate these lesions is heavily influenced by localized metabolic disruptions [5, 4]. A newly published study maps the specific enzymatic and epigenetic failures that stall this cellular maturation. The findings offer a distinct metabolic target for restoring myelin in the central nervous system by demonstrating that oligodendrocytes in demyelinating lesions undergo lactylation silencing (the loss of a lactate-driven epigenetic modification) and that overexpressing lactate dehydrogenase A in Olig1-positive precursor cells significantly enhances remyelination [6].

Glycolytic Failure in Demyelinating Lesions

To understand why myelin repair stalls in neurological diseases, the researchers investigated the metabolic state of the cells responsible for generating new myelin sheaths. They discovered a fundamental energy deficit at the site of injury. Specifically, the study demonstrated that oligodendrocytes located within demyelinating lesions exhibit reduced glycolytic efficiency compared with mature oligodendrocytes. Glycolysis (the metabolic pathway that converts glucose into cellular energy) is critical for meeting the high metabolic demands of synthesizing myelin. When this pathway falters, the precursor cells lack the energetic resources required to mature and wrap exposed axons. Furthermore, this glycolytic failure leads to a specific downstream shortage. The researchers found that oligodendrocytes within demyelinating lesions exhibit reduced lactate production compared with mature oligodendrocytes. Lactate is the primary end product of glycolysis in these cells and serves not just as a metabolic byproduct, but as a crucial signaling molecule. For practicing physicians managing demyelinating disorders, this indicates that the hostile environment of a plaque is characterized by a localized starvation of both energy and essential metabolic signals. This dual deficit prevents the resident precursor cells from completing their maturation cycle, effectively halting the remyelination process before it can begin.

Lactate and LDHA Drive Remyelination

To determine if correcting this metabolic deficit could restore myelin repair, the researchers tested direct interventions in the glycolytic pathway. They found that administration of lactate, the product of glycolysis, significantly enhances remyelination in animal models. Because systemic administration may lack cellular precision, the investigators also targeted the enzymatic machinery directly within the precursor cells. They demonstrated that specific overexpression of lactate dehydrogenase A (LDHA), the enzyme in lactate production, in Olig1-positive oligodendrocytes significantly enhances remyelination. Olig1 is a transcription factor that marks early-stage myelin-producing cells, and targeting this specific lineage ensures the intervention reaches the cells responsible for repair. For clinicians, this suggests that bypassing the metabolic bottleneck by either supplying the missing metabolite or boosting its local enzymatic production can successfully restart the stalled maturation of oligodendrocyte precursors. Conversely, removing this metabolic pathway underscores its absolute necessity for healthy central nervous system development and maintenance. The researchers observed that conditional knockout of LDHA in the Olig1-positive lineage leads to severe neuropathy with dysmyelination. This profound disruption was not limited to early precursors. The study also showed that conditional knockout of LDHA in CNPase-positive premyelinating oligodendrocytes leads to severe neuropathy with dysmyelination. CNPase is an enzyme expressed slightly later in the maturation process, just before active myelin wrapping begins. Importantly, the investigators noted that the severe neuropathy and dysmyelination caused by LDHA knockout occurs in a development-dependent and cell-specific manner. This indicates that the timing and cellular location of lactate production are critical for proper myelin formation, reinforcing the concept that targeted metabolic support could be a viable therapeutic strategy for demyelinating disorders where these specific cellular processes have failed.

The Epigenetic Role of Protein Lactylation

To understand the mechanistic link between cellular metabolism and myelin repair, the researchers investigated how lactate influences gene expression. They determined that lactylation is a lactate-induced epigenetic modification, meaning that the metabolic byproduct directly alters how proteins and cellular pathways are regulated. In the context of neurological injury, this signaling mechanism is severely disrupted. The study revealed that oligodendrocytes within demyelinating lesions undergo lactylation silencing, effectively losing this critical epigenetic signal. For clinicians managing patients with demyelinating diseases, this finding explains why precursor cells fail to mature even when acute inflammation is medically controlled. Without the necessary lactate to drive these epigenetic changes, the cellular repair program stalls. The researchers confirmed that this lactylation silencing in oligodendrocytes impedes myelin restoration. The investigators then mapped the specific protein targets that rely on this epigenetic modification to drive cellular development. They discovered that the lactylation of LDHA couples glycolysis with oligodendrocyte maturation, creating a feedback mechanism where the enzyme responsible for producing lactate is itself regulated by the lactylation process. Furthermore, the study demonstrated that the lactylation of carbonic anhydrase II (CAII) couples glycolysis with oligodendrocyte maturation. Carbonic anhydrase II is an enzyme critical for maintaining intracellular pH and fluid balance, and its regulation by lactate highlights a complex metabolic network required for myelin synthesis. By identifying these specific molecular targets, the findings illustrate exactly how metabolic failure translates into structural neurological deficits, offering precise enzymatic pathways that future therapies could target to stimulate myelin repair.

Clinical Implications for Demyelinating Disorders

For practicing neurologists and primary care physicians, understanding the cellular environment of a lesion is critical for managing long-term patient outcomes. As the researchers note, myelin injury is a hallmark of several neurological diseases and is highly sensitive to glucose metabolism disruptions. When the local energy supply falters, the structural integrity of the nerve fibers is compromised, leading to the progressive clinical decline seen in patients. By mapping the exact biochemical pathways that fail within these lesions, the findings elucidate the metabolic interplay among glycolysis, lactylation, and oligodendrocyte maturation. Specifically, the study clarifies how the breakdown of glucose into cellular energy (glycolysis) produces lactate, which then acts as an essential epigenetic switch (lactylation) to drive the final stages of myelin-producing cell development. Translating these cellular mechanisms into clinical practice addresses a major unmet need in the treatment of neurodegenerative conditions. Currently, physicians rely on immunomodulatory drugs that successfully suppress acute inflammatory attacks but fail to repair existing structural damage. Because the study provides enzymatic therapeutic perspectives for demyelinating disorders, which currently lack effective therapies, it opens a distinct avenue for drug development. Rather than solely targeting the immune system, future pharmacological interventions could be designed to upregulate specific enzymes like lactate dehydrogenase A directly within the central nervous system. By restoring local lactate production and overcoming epigenetic silencing, clinicians may eventually have the tools to stimulate active myelin repair and halt disease progression in their patients.

References

1. Dobson R, Giovannoni G. Multiple sclerosis – a review. European Journal of Neurology. 2018. doi:10.1111/ene.13819

2. Trapp BD, Peterson JW, Ransohoff RM, Rudick RA, Mørk S, Bø L. Axonal Transection in the Lesions of Multiple Sclerosis. New England Journal of Medicine. 1998. doi:10.1056/nejm199801293380502

3. Emery B. Regulation of Oligodendrocyte Differentiation and Myelination. Science. 2010. doi:10.1126/science.1190927

4. Stadelmann C, Timmler S, Barrantes‐Freer A, Simons M. Myelin in the Central Nervous System: Structure, Function, and Pathology. Physiological Reviews. 2019. doi:10.1152/physrev.00031.2018

5. Sajad M, Zahoor I, Rashid F, Cerghet M, Rattan R, Giri S. Pyruvate Dehydrogenase-Dependent Metabolic Programming Affects the Oligodendrocyte Maturation and Remyelination.. Molecular neurobiology. 2024. doi:10.1007/s12035-023-03546-x

6. Bao M, Li X, Sun Q, et al. Oligodendrocyte-encoded lactate dehydrogenase A couples glycolysis to remyelination via protein lactylation.. Neuron. 2026. doi:10.1016/j.neuron.2026.02.032